Agrawal Pankaj B, Wang Ruobing, Li Hongmei Lisa, Schmitz-Abe Klaus, Simone-Roach Chantelle, Chen Jingxin, Shi Jiahai, Louie Tin, Sheng Shaohu, Towne Meghan C, Brainson Christine F, Matthay Michael A, Kim Carla F, Bamshad Michael, Emond Mary J, Gerard Norma P, Kleyman Thomas R, Gerard Craig
Divisions of 1 Newborn Medicine.
2 Genetics and Genomics.
Am J Respir Cell Mol Biol. 2017 Dec;57(6):711-720. doi: 10.1165/rcmb.2017-0166OC.
Cystic fibrosis (CF) remains the most lethal genetic disease in the Caucasian population. However, there is great variability in clinical phenotypes and survival times, even among patients harboring the same genotype. We identified five patients with CF and a homozygous F508del mutation in the CFTR gene who were in their fifth or sixth decade of life and had shown minimal changes in lung function over a longitudinal period of more than 20 years. Because of the rarity of this long-term nonprogressive phenotype, we hypothesized these individuals may carry rare genetic variants in modifier genes that ameliorate disease severity. Individuals at the extremes of survival time and lung-function trajectory underwent whole-exome sequencing, and the sequencing data were filtered to include rare missense, stopgain, indel, and splicing variants present with a mean allele frequency of <0.2% in general population databases. Epithelial sodium channel (ENaC) mutants were generated via site-directed mutagenesis and expressed for Xenopus oocyte assays. Four of the five individuals carried extremely rare or never reported variants in the SCNN1D and SCNN1B genes of the ENaC. Separately, an independently enriched rare variant in SCNN1D was identified in the Exome Variant Server database associated with a milder pulmonary disease phenotype. Functional analysis using Xenopus oocytes revealed that two of the three variants in δ-ENaC encoded by SCNN1D exhibited hypomorphic channel activity. Our data suggest a potential role for δ-ENaC in controlling sodium reabsorption in the airways, and advance the plausibility of ENaC as a therapeutic target in CF.
囊性纤维化(CF)仍是白种人群中最致命的遗传性疾病。然而,即使在携带相同基因型的患者中,临床表型和生存时间也存在很大差异。我们鉴定出5例CF患者,他们的CFTR基因存在纯合F508del突变,年龄在五、六十岁,并且在超过20年的纵向观察期内肺功能变化极小。由于这种长期非进行性表型非常罕见,我们推测这些个体可能在修饰基因中携带罕见的遗传变异,从而减轻了疾病的严重程度。对生存时间和肺功能轨迹处于极端情况的个体进行了全外显子组测序,并对测序数据进行筛选,以纳入在一般人群数据库中平均等位基因频率<0.2%的罕见错义、终止密码子获得、插入缺失和剪接变异。通过定点诱变产生上皮钠通道(ENaC)突变体,并在非洲爪蟾卵母细胞试验中进行表达。这5例个体中有4例在ENaC的SCNN1D和SCNN1B基因中携带极其罕见或从未报道过的变异。另外,在外显子变异服务器数据库中鉴定出一个在SCNN1D中独立富集的罕见变异,其与较轻的肺部疾病表型相关。使用非洲爪蟾卵母细胞进行的功能分析显示,由SCNN1D编码的δ-ENaC中的3个变异中有2个表现出功能减退的通道活性。我们的数据表明δ-ENaC在控制气道钠重吸收方面具有潜在作用,并提高了ENaC作为CF治疗靶点的合理性。